REMARKS/ARGUMENTS

The present amendment after final rejection cancels Claims 1-3, 5 and 10. Claims 4

and 7-9 stand canceled. New Claim 11 is sought to be added.

Upon entry of the amendment the claims will be 6 and 11.

Claim 6 is amended as suggested in the Advisory Action for favorable consideration

by the Examiner.

Basis for the recitation "treating hypertriglyceridemia" appears in the specification at

page 6, the paragraph at line 2. That a synergistically effective combination exists for the

stated purpose is demonstrated in the Example, pages 8-10, reinforced by the declaration of

Taro Aoki.

New Claim 11 depends from Claim 6 and presents the preferred species of the

components of the combination recited in Claim 6. No new issue arises since the

combination was recited in deleted Claim 10.

The amendments to the specification presented in the previously filed Amendment

After Final Rejection are resubmitted. The Advisory Action presents no criticism of these

amendments.

The cancellation of claims 1-3, 5 and 10 renders the rejections of them moot.

Entry of the amendments and favorable reconsideration is solicited. No new issues

are raised and the number of claims is reduced.

Respectfully submitted,

Customer Number

22850

Tel: (703) 413-3000 Fax: (703) 413 -2220

(OSMMN 06/04)

OBLON, SPIVAK, McCLELLAND,

MAIER & NEUSTADT, P.C.

Norman F. Oblon.

Milton Sterman

Registration No. 27,499

4